All News

The campaign, More to Parkinson’s, will focus on providing education about Parkinson’s related hallucinations.

Heidi Capozzi previously served as chief people officer for McDonald’s.

Approval of Livdelzi is based on results from the Phase III RESPONSE study, which demonstrated improved key biochemical markers and reduced pruritus.

UGN-102 has the potential to be the first FDA-approved treatment for low-grade intermediate-risk non-muscle invasive bladder cancer, UroGen says.

Approval of Nemluvio was based on positive results from the Phase III OLYMIA trials, which demonstrated significant itch reductions.

In an interview with Pharm Exec Associate Editor Don Tracy, Carlos Doti, VP, Head of Medical Affairs, US Oncology Business Unit, AstraZeneca, discusses a number of oncology targets in the works at AstraZeneca.

The company worked in partnership with Neurocode.

In an interview with Pharm Exec Associate Editor Don Tracy, Carlos Doti, VP, Head of Medical Affairs, US Oncology Business Unit, AstraZeneca, talks PARP inhibitors in cancer treatment and the history of Lynparza.

The Complete Response Letter stated that current data on midomafetamine capsules is insufficient for approval in treating patients with post-traumatic stress disorder.

Strategic imperatives for biotech firms in light of the latest market dynamics and investor behaviors.

Approval of neffy marks a significant advancement in epinephrine delivery, offering a less painful alternative to traditional needle injections.

As part of the acquisition of CN201, Curon is expected to receive an upfront payment of $700 million, with the opportunity to earn an additional $600 million in milestone payments linked to the drug's development and regulatory approval.

Lymphir is the first therapy to target the IL-2 receptor in the treatment of relapsed or refractory cutaneous T-cell lymphoma and the first FDA-approved product for Citius Pharmaceuticals.

Accelerated approval of Fabhalta for treating primary IgA nephropathy was based on positive results from the Phase III APPLAUSE-IgAN study.

Clinical trials for Crexont demonstrated a substantial increase in "Good On" time, representing a period without troubling adverse effects in patients with Parkinson disease.

The two companies will combine assets to develop a device that make automatic adjustments.

Independence Blue Cross and Jefferson health published a study detailing the impact of such care.

Partnership with Abbott for Simplera CGM will expand access to the advanced automated insulin delivery.

The study aims to explore Anktiva as a potential cornerstone of future immunotherapy treatments for endometrial cancer and other forms of the disease.

Voranigo is the first targeted therapy in almost 25 years to be approved by the FDA for grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

The life sciences technology company will be able to offer services to the pharmacies associated with Legacy.

In an interview with Pharm Exec Associate Editor Don Tracy, Carlos Doti, VP, head of medical affairs, US oncology business unit, AstraZeneca, provides an update on current research efforts for Lynparza and discusses its impact on cancer patients over the past decade.

The FINEARTS-HF study, which compared Kerendia to a placebo when added to standard therapy, met its primary endpoint by reducing cardiovascular death and total heart failure events.

The collaboration will see both companies jointly develop and commercialize MK-6070 worldwide, except in Japan, where Merck retains exclusive rights.

A robust market access strategy ensures that pharmaceutical products, including those with limited distribution, reach patients and are covered by diverse healthcare systems.

Respondents said logistic reasons kept them from going to the doctor.

Expanded indication makes Fibryga the first and only on-demand, virus-inactivated, human plasma-derived fibrinogen concentrate approved for this indication.

The acquisition of Ypsomed’s pen needles and blood glucose monitoring system is expected to increase MTD’s production capacity to over 2.5 billion units.